Recent progress in therapeutic treatments and screening strategies for the prevention and treatment of HPV-associated head and neck cancer

Viruses

Volumn 7, Issue 9, 2015, Pages 5040-5065

  Whang, Sonia N ^a   Filippova, Maria ^a   Duerksen Hughes, Penelope ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer treatments; Head and neck squamous cell carcinoma; High risk HPV; HNSCC; HPV related oropharyngeal squamous cell carcinoma; HR HPV; OPSCC; Target therapy

Indexed keywords

AFATINIB; APTAMER; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA VACCINE; DOCETAXEL; FLUOROURACIL; GEFITINIB; LAPATINIB; METHOTREXATE; MONTANIDE ISA 51; NIMOTUZUMAB; NUTLIN 3; ONCOPROTEIN; PACLITAXEL; PANITUMUMAB; PROTEIN P16; PROTEIN P53; SMALL INTERFERING RNA; SORAFENIB; SUNITINIB; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG; VERPASEP CALTESPEN; VIRUS RNA; WART VIRUS VACCINE; ZALUTUMUMAB;

CANCER RADIOTHERAPY; CANCER SCREENING; CANCER THERAPY; CARCINOGENESIS; CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTENSITY MODULATED RADIATION THERAPY; MICROSURGERY; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; VIRUS DETECTION; VIRUS GENOME; WART VIRUS; CARCINOMA, SQUAMOUS CELL; COMPLICATION; EARLY CANCER DIAGNOSIS; HEAD AND NECK NEOPLASMS; IMMUNOLOGY; PAPILLOMAVIRUS INFECTIONS; PROCEDURES;

CARCINOMA, SQUAMOUS CELL; EARLY DETECTION OF CANCER; HEAD AND NECK NEOPLASMS; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 84941910974     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v7092860     Document Type: Review

References (169)

1. Bol, V.; Gregoire, V. Biological basis for increased sensitivity to radiation therapy in HPV-positive head and neck cancers. BioMed Res. Int. 2014, 2014, 696028.
2. Elrefaey, S.; Massaro, M.A.; Chiocca, S.; Chiesa, F.; Ansarin, M. HPV in oropharyngeal cancer: The basics to know in clinical practice. Acta Otorhinolaryngol. Ital. 2014, 34, 299–309.
3. Friedman, J.M.; Stavas, M.J.; Cmelak, A.J. Clinical and scientific impact of human papillomavirus on head and neck cancer. World J. Clin. Oncol. 2014, 5, 781–791.
4. Machiels, J.P.; Lambrecht, M.; Hanin, F.X.; Duprez, T.; Gregoire, V.; Schmitz, S.; Hamoir, M. Advances in the management of squamous cell carcinoma of the head and neck. F1000prime Rep.2014, 6, 44.
5. Van Kempen, P.M.; Noorlag, R.; Braunius, W.W.; Stegeman, I.; Willems, S.M.; Grolman, W. Differences in methylation profiles between HPV-positive and HPV-negative oropharynx squamous cell carcinoma: A systematic review. Epigenetics 2014, 9, 194–203.
6. Chai, R.C.; Lambie, D.; Verma, M.; Punyadeera, C. Current trends in the etiology and diagnosis of HPV-related head and neck cancers. Cancer Med. 2015, 4, 596–607.
7. John, K.; Wu, J.; Lee, B.W.; Farah, C.S. MicroRNAs in head and neck cancer. Int. J. Dent. 2013,2013, 650218.
8. Vermeer, D.W.; Spanos, W.C.; Vermeer, P.D.; Bruns, A.M.; Lee, K.M.; Lee, J.H. Radiation-induced loss of cell surface cd47 enhances immune-mediated clearance of human papillomavirus-positive cancer. Int. J. Cancer 2013, 133, 120–129.
9. Boscolo-Rizzo, P.; Del Mistro, A.; Bussu, F.; Lupato, V.; Baboci, L.; Almadori, G.; MC, D.A.M.; Paludetti, G. New insights into human papillomavirus-associated head and neck squamous cell carcinoma. Acta Otorhinolaryngol. Ital. 2013, 33, 77–87.
10. D'Souza, G.; Dempsey, A. The role of HPV in head and neck cancer and review of the HPV vaccine. Prev. Med. 2011, 53 (Suppl. 1), S5–S11.
11. Osazuwa-Peters, N.; Wang, D.D.; Namin, A.; Vivek, J.; O’Neill, M.; Patel, P.V.; Varvares, M.A. Sexual behavior, HPV knowledge, and association with head and neck cancer among a high-risk group. Oral Oncol. 2015, 51, 452–456.
12. Monnier, Y.; Simon, C. Surgery versus radiotherapy for early oropharyngeal tumors: A never-ending debate. Curr. Treat. Options Oncol. 2015, 16, 362.
13. Moore, K.A., 2nd; Mehta, V. The growing epidemic of HPV-positive oropharyngeal carcinoma: A clinical review for primary care providers. J. Am. Board Fam. Med. 2015, 28, 498–503.
14. Sepiashvili, L.; Bruce, J.P.; Huang, S.H.; O’Sullivan, B.; Liu, F.F.; Kislinger, T. Novel insights into head and neck cancer using next-generation "omic" technologies. Cancer Res. 2015, 75, 480–486.
15. Adams, A.K.; Wise-Draper, T.M.; Wells, S.I. Human papillomavirus induced transformation in cervical and head and neck cancers. Cancers 2014, 6, 1793–1820.
16. Antonsson, A.; Neale, R.E.; Boros, S.; Lampe, G.; Coman, W.B.; Pryor, D.I.; Porceddu, S.V.; Whiteman, D.C. Human papillomavirus status and p16 expression in patients with mucosal squamous cell carcinoma of the head and neck in queensland, australia. Cancer Epidemiol. 2015,39, 174–181.
17. Arbyn, M.; de Sanjose, S.; Saraiya, M.; Sideri, M.; Palefsky, J.; Lacey, C.; Gillison, M.; Bruni, L.; Ronco, G.; Wentzensen, N.; et al. Eurogin 2011 roadmap on prevention and treatment of HPV-related disease. Int. J. Cancer. 2012, 131, 1969–1982.
18. Bosch, F.X.; Broker, T.R.; Forman, D.; Moscicki, A.B.; Gillison, M.L.; Doorbar, J.; Stern, P.L.; Stanley, M.; Arbyn, M.; Poljak, M.; et al. Comprehensive control of human papillomavirus infections and related diseases. Vaccine 2013, 31 (Suppl. 8), I1–31.
19. Dalianis, T. Human papillomavirus (HPV) and oropharyngeal squamous cell carcinoma. Presse Med. (Paris, Fr. 1983) 2014, 43, e429–e434.
20. Ramshankar, V.; Krishnamurthy, A. Human papilloma virus in head and neck cancers-role and relevance in clinical management. Indian J. Surg. Oncol. 2013, 4, 59–66.
21. Chaturvedi, A.K.; Engels, E.A.; Pfeiffer, R.M.; Hernandez, B.Y.; Xiao, W.; Kim, E.; Jiang, B.; Goodman, M.T.; Sibug-Saber, M.; Cozen, W.; et al. Human papillomavirus and rising oropharyngeal cancer incidence in the united states. J. Clin. Oncol. 2011, 29, 4294–4301.
22. Gillison, M.L.; Koch, W.M.; Capone, R.B.; Spafford, M.; Westra, W.H.; Wu, L.; Zahurak, M.L.; Daniel, R.W.; Viglione, M.; Symer, D.E.; et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J. Natl. Cancer Inst. 2000, 92, 709–720.
23. Psyrri, A.; Sasaki, C.; Vassilakopoulou, M.; Dimitriadis, G.; Rampias, T. Future directions in research, treatment and prevention of HPV-related squamous cell carcinoma of the head and neck. Head Neck Pathol. 2012, 6 (Suppl. 1), S121–S128.
24. Urban, D.; Corry, J.; Rischin, D. What is the best treatment for patients with human papillomavirus-positive and -negative oropharyngeal cancer? Cancer 2014, 120, 1462–1470.
25. Garbuglia, A.R. Human papillomavirus in head and neck cancer. Cancers 2014, 6, 1705–1726.
26. Dalianis, T. Human papillomavirus and oropharyngeal cancer, the epidemics, and significance of additional clinical biomarkers for prediction of response to therapy (review). Int. J. Oncol. 2014,44, 1799–1805.
27. Dreyer, J.H.; Hauck, F.; Oliveira-Silva, M.; Barros, M.H.; Niedobitek, G. Detection of HPV infection in head and neck squamous cell carcinoma: A practical proposal. Virchows. Archiv.2013, 462, 381–389.
28. Bonilla-Velez, J.; Mroz, E.A.; Hammon, R.J.; Rocco, J.W. Impact of human papillomavirus on oropharyngeal cancer biology and response to therapy: Implications for treatment. Otolaryngol. Clin. N. Am. 2013, 46, 521–543.
29. Wierzbicka, M.; Jozefiak, A.; Szydlowski, J.; Marszalek, A.; Stankiewicz, C.; Hassman-Poznanska, E.; Osuch-Wojcikiewicz, E.; Skladzien, J.; Klatka, J.; Pietruszewska, W.; et al. Recommendations for the diagnosis of human papilloma virus (HPV) high and low risk in the prevention and treatment of diseases of the oral cavity, pharynx and larynx. Guide of experts ptorl and kidl. Otolaryngol. Pol. 2013, 67, 113–134.
30. Caicedo-Granados, E.; Lin, R.; Fujisawa, C.; Yueh, B.; Sangwan, V.; Saluja, A. Wild-type p53 reactivation by small-molecule minnelide in human papillomavirus (HPV)-positive head and neck squamous cell carcinoma. Oral Oncol. 2014, 50, 1149–1156.
31. Lui, V.W.; Grandis, J.R. Primary chemotherapy and radiation as a treatment strategy for HPV-positive oropharyngeal cancer. Head Neck Pathol. 2012, 6 (Suppl. 1), S91–S97.
32. Rettig, E.; Kiess, A.P.; Fakhry, C. The role of sexual behavior in head and neck cancer: Implications for prevention and therapy. Expert Rev. Anticancer ther. 2015, 15, 35–49.
33. Stanley, M.A. Genital human papillomavirus infections: Current and prospective therapies. J. Gen. Virol. 2012, 93, 681–691.
34. Mannarini, L.; Kratochvil, V.; Calabrese, L.; Gomes Silva, L.; Morbini, P.; Betka, J.; Benazzo, M. Human papilloma virus (HPV) in head and neck region: Review of literature. Acta Otorhinolaryngol. Ital. 2009, 29, 119–126.
35. Haedicke, J.; Iftner, T. Human papillomaviruses and cancer. Radiother. Oncol. 2013, 108, 397–402.
36. Langer, C.J. Exploring biomarkers in head and neck cancer. Cancer 2012, 118, 3882–3892.
37. Blitzer, G.C.; Smith, M.A.; Harris, S.L.; Kimple, R.J. Review of the clinical and biologic aspects of human papillomavirus-positive squamous cell carcinomas of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 2014, 88, 761–770.
38. Gillison, M.L.; Broutian, T.; Pickard, R.K.; Tong, Z.Y.; Xiao, W.; Kahle, L.; Graubard, B.I.; Chaturvedi, A.K. Prevalence of oral HPV infection in the united states, 2009–2010. Jama 2012,307, 693–703.
39. Nelke, K.H.; Lysenko, L.; Leszczyszyn, J.; Gerber, H. Human papillomavirus and its influence on head and neck cancer predisposition. Postepy higieny i medycyny doswiadczalnej (Online) 2013,67, 610–616.
40. D'Souza, G.; Agrawal, Y.; Halpern, J.; Bodison, S.; Gillison, M.L. Oral sexual behaviors associated with prevalent oral human papillomavirus infection. J. Infect. Dis. 2009, 199, 1263–1269.
41. Moscicki, A.B. Impact of HPV infection in adolescent populations. J. Adolesc. Health 2005, 37, S3–S9.
42. Best, S.R.; Niparko, K.J.; Pai, S.I. Biology of human papillomavirus infection and immune therapy for HPV-related head and neck cancers. Otolaryngol. Clin. N. Am. 2012, 45, 807–822.
43. D’Souza, G.; Kreimer, A.R.; Viscidi, R.; Pawlita, M.; Fakhry, C.; Koch, W.M.; Westra, W.H.; Gillison, M.L. Case-control study of human papillomavirus and oropharyngeal cancer. N. Engl. J. Med. 2007, 356, 1944–1956.
44. Pickard, R.K.; Xiao, W.; Broutian, T.R.; He, X.; Gillison, M.L. The prevalence and incidence of oral human papillomavirus infection among young men and women, aged 18–30 years. Sex. Transm. Dis. 2012, 39, 559–566.
45. Steinau, M.; Hariri, S.; Gillison, M.L.; Broutian, T.R.; Dunne, E.F.; Tong, Z.Y.; Markowitz, L.E.; Unger, E.R. Prevalence of cervical and oral human papillomavirus infections among us women. J. Infect. Dis. 2014, 209, 1739–1743.
46. Hemminki, K.; Dong, C.; Frisch, M. Tonsillar and other upper aerodigestive tract cancers among cervical cancer patients and their husbands. Eur. J. Cancer Prev. 2000, 9, 433–437.
47. Vogt, S.L.; Gravitt, P.E.; Martinson, N.A.; Hoffmann, J.; D’Souza, G. Concordant oral-genital HPV infection in south africa couples: Evidence for transmission. Front. Oncol. 2013, 3, 303.
48. Widdice, L.E.; Breland, D.J.; Jonte, J.; Farhat, S.; Ma, Y.; Leonard, A.C.; Moscicki, A.B. Human papillomavirus concordance in heterosexual couples. J. Adolesc. Health 2010, 47, 151–159.
49. Trosman, S.J.; Koyfman, S.A.; Ward, M.C.; Al-Khudari, S.; Nwizu, T.; Greskovich, J.F.; Lamarre, E.D.; Scharpf, J.; Khan, M.J.; Lorenz, R.R.; et al. Effect of human papillomavirus on patterns of distant metastatic failure in oropharyngeal squamous cell carcinoma treated with chemoradiotherapy. JAMA Otolaryngol. Head Neck Surg. 2015, 141, 457–462.
50. Cooper, T.; Biron, V.L.; Fast, D.; Tam, R.; Carey, T.; Shmulevitz, M.; Seikaly, H. Oncolytic activity of reovirus in HPV positive and negative head and neck squamous cell carcinoma. J. Otolaryngol. Head Neck Surg. 2015, 44.
51. Smith, E.M.; Ritchie, J.M.; Summersgill, K.F.; Klussmann, J.P.; Lee, J.H.; Wang, D.; Haugen, T.H.; Turek, L.P. Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. Int. J. Cancer. 2004, 108, 766–772.
52. Duek, I.; Billan, S.; Amit, M.; Gil, Z. Transoral robotic surgery in the HPV era. Rambam Maimonides Med. J. 2014, 5, e0010.
53. Genden, E.M. The role for surgical management of HPV-related oropharyngeal carcinoma. Head Neck Pathol. 2012, 6 (Suppl. 1), S98–S103.
54. Lorincz, B.B.; Jowett, N.; Knecht, R. Decision management in transoral robotic surgery (tors): Indications, individual patient selection, and role in the multidisciplinary treatment of head and neck cancer from a european perspective. Head Neck 2015.
55. Nichols, A.C.; Yoo, J.; Hammond, J.A.; Fung, K.; Winquist, E.; Read, N.; Venkatesan, V.; MacNeil, S.D.; Ernst, D.S.; Kuruvilla, S.; et al. Early-stage squamous cell carcinoma of the oropharynx: Radiotherapy vs. Trans-oral robotic surgery (orator)—Study protocol for a randomized phase ii trial. BMC Cancer 2013, 13.
56. Sanders, A.E.; Slade, G.D.; Patton, L.L. National prevalence of oral HPV infection and related risk factors in the U.S. Adult population. Oral Dis. 2012, 18, 430–441.
57. Zhang, P.; Mirani, N.; Baisre, A.; Fernandes, H. Molecular heterogeneity of head and neck squamous cell carcinoma defined by next-generation sequencing. Am. J. Pathol. 2014, 184, 1323–1330.
58. Settle, K.; Posner, M.R.; Schumaker, L.M.; Tan, M.; Suntharalingam, M.; Goloubeva, O.; Strome, S.E.; Haddad, R.I.; Patel, S.S.; Cambell, E.V., 3rd; et al. Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev. Res. (Phil., PA.) 2009, 2, 776–781.
59. Weinberger, P.M.; Merkley, M.A.; Khichi, S.S.; Lee, J.R.; Psyrri, A.; Jackson, L.L.; Dynan, W.S. Human papillomavirus-active head and neck cancer and ethnic health disparities. Laryngoscope2010, 120, 1531–1537.
60. Fumagalli, I.; Dugue, D.; Bibault, J.E.; Clemenson, C.; Vozenin, M.C.; Mondini, M.; Deutsch, E. Cytotoxic effect of lapatinib is restricted to human papillomavirus-positive head and neck squamous cell carcinoma cell lines. OncoTargets Ther. 2015, 8, 335–345.
61. Kaczmar, J.M.; Tan, K.S.; Heitjan, D.F.; Lin, A.; Ahn, P.H.; Newman, J.G.; Rassekh, C.H.; Chalian, A.A.; O'Malley, B.W., Jr.; Cohen, R.B.; et al. HPV-related oropharyngeal cancer: Risk factors for treatment failure in patients managed with primary transoral robotic surgery. Head & Neck 2014.
62. Mydlarz, W.K.; Chan, J.Y.; Richmon, J.D. The role of surgery for HPV-associated head and neck cancer. Oral Oncol. 2015, 51, 305–313.
63. Ang, K.K.; Harris, J.; Wheeler, R.; Weber, R.; Rosenthal, D.I.; Nguyen-Tan, P.F.; Westra, W.H.; Chung, C.H.; Jordan, R.C.; Lu, C.; et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N. Engl. J. Med. 2010, 363, 24–35.
64. George, M. Should patients with HPV-positive or negative tumors be treated differently? Curr. Oncol. Rep. 2014, 16, 384.
65. Guo, T.; Qualliotine, J.R.; Ha, P.K.; Califano, J.A.; Kim, Y.; Saunders, J.R.; Blanco, R.G.; D’Souza, G.; Zhang, Z.; Chung, C.H.; et al. Surgical salvage improves overall survival for patients with HPV-positive and HPV-negative recurrent locoregional and distant metastatic oropharyngeal cancer. Cancer 2015, 121, 1977–1984.
66. Maxwell, J.H.; Mehta, V.; Wang, H.; Cunningham, D.; Duvvuri, U.; Kim, S.; Johnson, J.T.; Ferris, R.L. Quality of life in head and neck cancer patients: Impact of HPV and primary treatment modality. Laryngoscope 2014, 124, 1592–1597.
67. Martinez-Useros, J.; Garcia-Foncillas, J. The challenge of blocking a wider family members of egfr against head and neck squamous cell carcinomas. Oral Oncol. 2015, 51, 423–430.
68. Purohit, S.; Bhise, R.; Lokanatha, D.; Govindbabu, K. Systemic therapy in head and neck cancer: Changing paradigm. Indian J. Surg. Oncol. 2013, 4, 19–26.
69. Bernier, J.; Domenge, C.; Ozsahin, M.; Matuszewska, K.; Lefebvre, J.L.; Greiner, R.H.; Giralt, J.; Maingon, P.; Rolland, F.; Bolla, M.; et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med. 2004, 350, 1945–1952.
70. Cooper, J.S.; Pajak, T.F.; Forastiere, A.A.; Jacobs, J.; Campbell, B.H.; Saxman, S.B.; Kish, J.A.; Kim, H.E.; Cmelak, A.J.; Rotman, M.; et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 2004,350, 1937–1944.
71. Burtness, B.; Bourhis, J.P.; Vermorken, J.B.; Harrington, K.J.; Cohen, E.E. Afatinib versusplacebo as adjuvant therapy after chemoradiation in a double-blind, phase iii study (lux-head & neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: Study protocol for a randomized controlled trial. Trials 2014, 15, 469.
72. Hamoir, M.; Ferlito, A.; Schmitz, S.; Hanin, F.X.; Thariat, J.; Weynand, B.; Machiels, J.P.; Gregoire, V.; Robbins, K.T.; Silver, C.E.; et al. The role of neck dissection in the setting of chemoradiation therapy for head and neck squamous cell carcinoma with advanced neck disease. Oral Oncol. 2012, 48, 203–210.
73. Patel, S.N.; Cohen, M.A.; Givi, B.; Dixon, B.J.; Gilbert, R.W.; Gullane, P.J.; Brown, D.H.; Irish, J.C.; de Almeida, J.R.; Higgins, K.M.; et al. Salvage surgery of locally recurrent oropharyngeal cancer. Head & Neck 2015.
74. Modur, V.; Thomas-Robbins, K.; Rao, K. HPV and csc in hnscc cisplatin resistance. Front. Biosci. (Elite ed.) 2015, 7, 58–66.
75. Ford, S.E.; Brandwein-Gensler, M.; Carroll, W.R.; Rosenthal, E.L.; Magnuson, J.S. Transoral robotic versus open surgical approaches to oropharyngeal squamous cell carcinoma by human papillomavirus status. Otolaryngol. Head Neck Surg. 2014, 151, 606–611.
76. Ridge, J.A. Surgery in the HPV era: The role of robotics and microsurgical techniques. Am. Soc. Clin. Oncol. Educ. Book 2014, 154–159.
77. Hinni, M.L.; Nagel, T.; Howard, B. Oropharyngeal cancer treatment: The role of transoral surgery.Curr. Opin. Otolaryngol. Head Neck Surg. 2015, 23, 132–138.
78. O'Leary, P.; Kjaergaard, T. Transoral robotic surgery and oropharyngeal cancer: A literature review. Ear Nose Throat J. 2014, 93, E14–E21.
79. Forastiere, A.A.; Goepfert, H.; Maor, M.; Pajak, T.F.; Weber, R.; Morrison, W.; Glisson, B.; Trotti, A.; Ridge, J.A.; Chao, C.; et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N. Engl. J. Med. 2003, 349, 2091–2098.
80. Psyrri, A.; Seiwert, T.Y.; Jimeno, A. Molecular pathways in head and neck cancer: Egfr, pi3k, and more. Am. Soc. Clin. Oncol. Educ. Book 2013, 246–255.
81. Malhotra, B.; Bellile, E.L.; Nguyen, N.P.; Fung, V.K.; Slack, M.; Bilich, R.; Papagerakis, S.; Worden, F. Carboplatin-pemetrexed in treatment of patients with recurrent/metastatic cancers of the head and neck; superior outcomes in oropharyngeal primaries. Front. Oncol. 2014, 4, 362.
82. Inhestern, J.; Oertel, K.; Stemmann, V.; Schmalenberg, H.; Dietz, A.; Rotter, N.; Veit, J.; Gorner, M.; Sudhoff, H.; Junghanss, C.; et al. Prognostic role of circulating tumor cells during induction chemotherapy followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer. PLoS ONE 2015, 10, e0132901.
83. Hsu, H.W.; Wall, N.R.; Hsueh, C.T.; Kim, S.; Ferris, R.L.; Chen, C.S.; Mirshahidi, S. Combination antiangiogenic therapy and radiation in head and neck cancers. Oral Oncol. 2014,50, 19–26.
84. McBride, S.M.; Parambi, R.J.; Jang, J.W.; Goldsmith, T.; Busse, P.M.; Chan, A.W. Intensity-modulated versus conventional radiation therapy for oropharyngeal carcinoma: Long-term dysphagia and tumor control outcomes. Head Neck 2014, 36, 492–498.
85. Surucu, M.; Shah, K.K.; Mescioglu, I.; Roeske, J.C.; Small, W., Jr.; Choi, M.; Emami, B. Decision trees predicting tumor shrinkage for head and neck cancer: Implications for adaptive radiotherapy. Technol. Cancer Res. Treat. 2015. (Epub ahead of print).
86. Broglie, M.A.; Soltermann, A.; Rohrbach, D.; Haile, S.R.; Pawlita, M.; Studer, G.; Huber, G.F.; Moch, H.; Stoeckli, S.J. Impact of p16, p53, smoking, and alcohol on survival in patients with oropharyngeal squamous cell carcinoma treated with primary intensity-modulated chemoradiation. Head Neck 2013, 35, 1698–1706.
87. Coppock, J.D.; Wieking, B.G.; Molinolo, A.A.; Gutkind, J.S.; Miskimins, W.K.; Lee, J.H. Improved clearance during treatment of HPV-positive head and neck cancer through mtor inhibition. Neoplasia (New York, N.Y.) 2013, 15, 620–630.
88. Kumar, B.; Cordell, K.G.; Lee, J.S.; Prince, M.E.; Tran, H.H.; Wolf, G.T.; Urba, S.G.; Worden, F.P.; Chepeha, D.B.; Teknos, T.N.; et al. Response to therapy and outcomes in oropharyngeal cancer are associated with biomarkers including human papillomavirus, epidermal growth factor receptor, gender, and smoking. Int. J. Radiat. Oncol. Biol. Phys. 2007, 69, S109–S111.
89. Lohaus, F.; Linge, A.; Tinhofer, I.; Budach, V.; Gkika, E.; Stuschke, M.; Balermpas, P.; Rodel, C.; Avlar, M.; Grosu, A.L.; et al. HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the german cancer consortium radiation oncology group (dktk-rog). Radiother. Oncol. 2014, 113, 317–323.
90. Stern, P.L.; van der Burg, S.H.; Hampson, I.N.; Broker, T.R.; Fiander, A.; Lacey, C.J.; Kitchener, H.C.; Einstein, M.H. Therapy of human papillomavirus-related disease. Vaccine 2012, 30 (Suppl. 5), F71–F82.
91. Fakhry, C.; Westra, W.H.; Li, S.; Cmelak, A.; Ridge, J.A.; Pinto, H.; Forastiere, A.; Gillison, M.L. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J. Natl. Cancer Instit. 2008, 100, 261–269.
92. Rischin, D.; Young, R.J.; Fisher, R.; Fox, S.B.; Le, Q.T.; Peters, L.J.; Solomon, B.; Choi, J.; O'Sullivan, B.; Kenny, L.M.; et al. Prognostic significance of p16ink4a and human papillomavirus in patients with oropharyngeal cancer treated on trog 02.02 phase iii trial. J. Clin. Oncol. 2010, 28, 4142–4148.
93. Laskar, S.G.; Swain, M. HPV positive oropharyngeal cancer and treatment deintensification: How pertinent is it? J. Cancer Res. Ther. 2015, 11, 6–9.
94. Amine, A.; Rivera, S.; Opolon, P.; Dekkal, M.; Biard, D.S.; Bouamar, H.; Louache, F.; McKay, M.J.; Bourhis, J.; Deutsch, E.; et al. Novel anti-metastatic action of cidofovir mediated by inhibition of E6/E7, CXCR4 and rho/ROCK signaling in HPV tumor cells. PLoS ONE 2009, 4, e5018.
95. Turner, D.O.; Williams-Cocks, S.J.; Bullen, R.; Catmull, J.; Falk, J.; Martin, D.; Mauer, J.; Barber, A.E.; Wang, R.C.; Gerstenberger, S.L.; et al. High-risk human papillomavirus (HPV) screening and detection in healthy patient saliva samples: A pilot study. BMC Oral Health 2011, 11, 28.
96. Fertig, E.J.; Markovic, A.; Danilova, L.V.; Gaykalova, D.A.; Cope, L.; Chung, C.H.; Ochs, M.F.; Califano, J.A. Preferential activation of the hedgehog pathway by epigenetic modulations in HPV negative hnscc identified with meta-pathway analysis. PLoS ONE 2013, 8, e78127.
97. Masterson, L.; Moualed, D.; Liu, Z.W.; Howard, J.E.; Dwivedi, R.C.; Tysome, J.R.; Benson, R.; Sterling, J.C.; Sudhoff, H.; Jani, P.; et al. De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma: A systematic review and meta-analysis of current clinical trials. Eur. J. Cancer (Oxf., Engl. 1990) 2014, 50, 2636–2648.
98. Syrjanen, K.J.; Pyrhonen, S.; Syrjanen, S.M.; Lamberg, M.A. Immunohistochemical demonstration of human papilloma virus (HPV) antigens in oral squamous cell lesions. Br. J. Oral Surg. 1983,21, 147–153.
99. Langevin, S.M.; Grandis, J.R.; Taioli, E. Female hormonal and reproductive factors and head and neck squamous cell carcinoma risk. Cancer Lett. 2011, 310, 216–221.
100. Jeon, S.; Allen-Hoffmann, B.L.; Lambert, P.F. Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J. Virol. 1995, 69, 2989–2997.
101. Yu, T.; Ferber, M.J.; Cheung, T.H.; Chung, T.K.; Wong, Y.F.; Smith, D.I. The role of viral integration in the development of cervical cancer. Cancer Genet. Cytogenet. 2005, 158, 27–34.
102. Gao, G.; Johnson, S.H.; Kasperbauer, J.L.; Eckloff, B.W.; Tombers, N.M.; Vasmatzis, G.; Smith, D.I. Mate pair sequencing of oropharyngeal squamous cell carcinomas reveals that HPV integration occurs much less frequently than in cervical cancer. J. Clin. Virol. 2014, 59, 195–200.
103. Olthof, N.C.; Huebbers, C.U.; Kolligs, J.; Henfling, M.; Ramaekers, F.C.; Cornet, I.; van Lent-Albrechts, J.A.; Stegmann, A.P.; Silling, S.; Wieland, U.; et al. Viral load, gene expression and mapping of viral integration sites in HPV16-associated hnscc cell lines. Int. J. Cancer 2015, 136, E207–E218.
104. Koskinen, W.J.; Chen, R.W.; Leivo, I.; Makitie, A.; Back, L.; Kontio, R.; Suuronen, R.; Lindqvist, C.; Auvinen, E.; Molijn, A.; et al. Prevalence and physical status of human papillomavirus in squamous cell carcinomas of the head and neck. Int. J. Cancer 2003, 107, 401–406.
105. Albers, A.; Abe, K.; Hunt, J.; Wang, J.; Lopez-Albaitero, A.; Schaefer, C.; Gooding, W.; Whiteside, T.L.; Ferrone, S.; DeLeo, A.; et al. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. Cancer Res. 2005, 65, 11146–11155.
106. Rein, D.T.; Kurbacher, C.M. The role of chemotherapy in invasive cancer of the cervix uteri: Current standards and future prospects. Anti-Cancer Drugs 2001, 12, 787–795.
107. Kumar, S.; Biswas, M.; Jose, T. HPV vaccine: Current status and future directions. Med. J. Armed Forces India 2015, 71, 171–177.
108. Cubie, H.A.; Cuschieri, K. Understanding HPV tests and their appropriate applications. Cytopathology 2013, 24, 289–308.
109. Nicol, C.; Cesur, O.; Forrest, S.; Belyaeva, T.A.; Bunka, D.H.; Blair, G.E.; Stonehouse, N.J. An RNA aptamer provides a novel approach for the induction of apoptosis by targeting the HPV16 E7 oncoprotein. PLoS ONE 2013, 8, e64781.
110. Parkin, D.M. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 2006, 118, 3030–3044.
111. Lin, K.; Doolan, K.; Hung, C.F.; Wu, T.C. Perspectives for preventive and therapeutic HPV vaccines. J. Formos. Med. Assoc. = Taiwan yi zhi 2010, 109, 4–24.
112. D’Abramo, C.M.; Archambault, J. Small molecule inhibitors of human papillomavirus protein—Protein interactions. Open Virol. J. 2011, 5, 80–95.
113. Blioumi, E.; Chatzidimitriou, D.; Pazartzi, C.; Katopodi, T.; Tzimagiorgis, G.; Emmanouil-Nikoloussi, E.N.; Markopoulos, A.; Kalekou, C.; Lazaridis, N.; Diza, E.; et al. Detection and typing of human papillomaviruses (HPV) in malignant, dysplastic, nondysplastic and normal oral epithelium by nested polymerase chain reaction, immunohistochemistry and transitional electron microscopy in patients of northern greece. Oral Oncol. 2014, 50, 840–847.
114. Almajhdi, F.N.; Senger, T.; Amer, H.M.; Gissmann, L.; Ohlschlager, P. Design of a highly effective therapeutic HPV16 E6/E7-specific DNA vaccine: Optimization by different ways of sequence rearrangements (shuffling). PLoS ONE 2014, 9, e113461.
115. Yuan, C.H.; Filippova, M.; Duerksen-Hughes, P. Modulation of apoptotic pathways by human papillomaviruses (HPV): Mechanisms and implications for therapy. Viruses 2012, 4, 3831–3850.
116. Devaraj, K.; Gillison, M.L.; Wu, T.C. Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma. Crit. Rev. Oral Biol. Med. 2003, 14, 345–362.
117. Grasso, F.; Negri, D.R.; Mochi, S.; Rossi, A.; Cesolini, A.; Giovannelli, A.; Chiantore, M.V.; Leone, P.; Giorgi, C.; Cara, A. Successful therapeutic vaccination with integrase defective lentiviral vector expressing nononcogenic human papillomavirus E7 protein. Int. J. Cancer 2013,132, 335–344.
118. Ma, B.; Maraj, B.; Tran, N.P.; Knoff, J.; Chen, A.; Alvarez, R.D.; Hung, C.F.; Wu, T.C. Emerging human papillomavirus vaccines. Expert Opin. Emerg. Drugs 2012, 17, 469–492.
119. Monie, A.; Tsen, S.W.; Hung, C.F.; Wu, T.C. Therapeutic HPV DNA vaccines. Expert Rev. Vaccines 2009, 8, 1221–1235.
120. Cherry, J.J.; Rietz, A.; Malinkevich, A.; Liu, Y.; Xie, M.; Bartolowits, M.; Davisson, V.J.; Baleja, J.D.; Androphy, E.J. Structure based identification and characterization of flavonoids that disrupt human papillomavirus-16 E6 function. PLoS ONE 2013, 8, e84506.
121. Scheffner, M.; Werness, B.A.; Huibregtse, J.M.; Levine, A.J.; Howley, P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990,63, 1129–1136.
122. Lechner, M.S.; Laimins, L.A. Inhibition of p53 DNA binding by human papillomavirus E6 proteins. J. Virol. 1994, 68, 4262–4273.
123. Kennedy, E.M.; Kornepati, A.V.; Goldstein, M.; Bogerd, H.P.; Poling, B.C.; Whisnant, A.W.; Kastan, M.B.; Cullen, B.R. Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR-Cas RNA-guided endonuclease. J. Virol. 2014, 88, 11965–11972.
124. Hietanen, S.; Lain, S.; Krausz, E.; Blattner, C.; Lane, D.P. Activation of p53 in cervical carcinoma cells by small molecules. Proc. Natl. Acad. Sci. USA 2000, 97, 8501–8506.
125. Filippova, M.; Johnson, M.M.; Bautista, M.; Filippov, V.; Fodor, N.; Tungteakkhun, S.S.; Williams, K.; Duerksen-Hughes, P.J. The large and small isoforms of human papillomavirus type 16 E6 bind to and differentially affect procaspase 8 stability and activity. J. Virol. 2007, 81, 4116–4129.
126. Tungteakkhun, S.S.; Filippova, M.; Fodor, N.; Duerksen-Hughes, P.J. The full-length isoform of human papillomavirus 16 E6 and its splice variant E6* bind to different sites on the procaspase 8 death effector domain. J. Virol. 2010, 84, 1453–1463.
127. Filippova, M.; Parkhurst, L.; Duerksen-Hughes, P.J. The human papillomavirus 16 E6 protein binds to fas-associated death domain and protects cells from fas-triggered apoptosis. J. Biol. Chem. 2004, 279, 25729–25744.
128. Tungteakkhun, S.S.; Filippova, M.; Neidigh, J.W.; Fodor, N.; Duerksen-Hughes, P.J. The interaction between human papillomavirus type 16 and fadd is mediated by a novel E6 binding domain. J. Virol. 2008, 82, 9600–9614.
129. Tungteakkhun, S.S.; Duerksen-Hughes, P.J. Cellular binding partners of the human papillomavirus E6 protein. Arch. Virol. 2008, 153, 397–408.
130. Dyson, N.; Howley, P.M.; Munger, K.; Harlow, E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science (New York, N.Y.) 1989, 243, 934–937.
131. Boyer, S.N.; Wazer, D.E.; Band, V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 1996, 56, 4620–4624.
132. Liu, X.; Clements, A.; Zhao, K.; Marmorstein, R. Structure of the human papillomavirus E7 oncoprotein and its mechanism for inactivation of the retinoblastoma tumor suppressor. J. Biol. Chem. 2006, 281, 578–586.
133. Kreimer, A.R. Prospects for prevention of HPV-driven oropharynx cancer. Oral Oncol. 2014, 50, 555–559.
134. Bishop, J.A.; Lewis, J.S., Jr.; Rocco, J.W.; Faquin, W.C. HPV-related squamous cell carcinoma of the head and neck: An update on testing in routine pathology practice. Semin. Diagn. Pathol.2015.
135. Jarboe, E.A.; Hunt, J.P.; Layfield, L.J. Cytomorphologic diagnosis and HPV testing of metastatic and primary oropharyngeal squamous cell carcinomas: A review and summary of the literature. Diagn. Cytopathol. 2012, 40, 491–497.
136. Linxweiler, M.; Bochen, F.; Wemmert, S.; Lerner, C.; Hasenfus, A.; Bohle, R.M.; Al-Kadah, B.; Takacs, Z.F.; Smola, S.; Schick, B. Combination of p16(ink4a) /ki67 immunocytology and HPV polymerase chain reaction for the noninvasive analysis of HPV involvement in head and neck cancer. Cancer Cytopathol. 2015, 123, 219–229.
137. Dictor, M.; Warenholt, J. Single-tube multiplex pcr using type-specific E6/E7 primers and capillary electrophoresis genotypes 21 human papillomaviruses in neoplasia. Infect. Agents Cancer 2011, 6, 1.
138. Weiss, D.; Heinkele, T.; Rudack, C. Reliable detection of human papillomavirus in recurrent laryngeal papillomatosis and associated carcinoma of archival tissue. J. Med. Virol. 2015, 87, 860–870.
139. Melkane, A.E.; Mirghani, H.; Auperin, A.; Saulnier, P.; Lacroix, L.; Vielh, P.; Casiraghi, O.; Griscelli, F.; Temam, S. HPV-related oropharyngeal squamous cell carcinomas: A comparison between three diagnostic approaches. Am. J. Otolaryngol. 2014, 35, 25–32.
140. Wittekindt, C.; Wagner, S.; Klussmann, J.P. [HPV-associated head and neck cancer. The basics of molecular and translational research]. Hno 2011, 59, 885–892.
141. Ahn, S.M.; Chan, J.Y.; Zhang, Z.; Wang, H.; Khan, Z.; Bishop, J.A.; Westra, W.; Koch, W.M.; Califano, J.A. Saliva and plasma quantitative polymerase chain reaction-based detection and surveillance of human papillomavirus-related head and neck cancer. JAMA Otolaryngol. Head Neck Surg. 2014, 140, 846–854.
142. Kelesidis, T.; Aish, L.; Steller, M.A.; Aish, I.S.; Shen, J.; Foukas, P.; Panayiotides, J.; Petrikkos, G.; Karakitsos, P.; Tsiodras, S. Human papillomavirus (HPV) detection using in situ hybridization in histologic samples: Correlations with cytologic changes and polymerase chain reaction HPV detection. Am. J. Clin. Pathol. 2011, 136, 119–127.
143. Kimple, A.J.; Torres, A.D.; Yang, R.Z.; Kimple, R.J. HPV-associated head and neck cancer: Molecular and nano-scale markers for prognosis and therapeutic stratification. Sensors (Basel, Switz.) 2012, 12, 5159–5169.
144. Duncan, L.D.; Winkler, M.; Carlson, E.R.; Heidel, R.E.; Kang, E.; Webb, D. P16 immunohistochemistry can be used to detect human papillomavirus in oral cavity squamous cell carcinoma. J. Oral Maxillofac. Surg. 2013, 71, 1367–1375.
145. Smeets, S.J.; Hesselink, A.T.; Speel, E.J.; Haesevoets, A.; Snijders, P.J.; Pawlita, M.; Meijer, C.J.; Braakhuis, B.J.; Leemans, C.R.; Brakenhoff, R.H. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int. j. Cancer 2007,121, 2465–2472.
146. Bishop, J.A.; Ma, X.J.; Wang, H.; Luo, Y.; Illei, P.B.; Begum, S.; Taube, J.M.; Koch, W.M.; Westra, W.H. Detection of transcriptionally active high-risk HPV in patients with head and neck squamous cell carcinoma as visualized by a novel E6/E7 mRNA in situ hybridization method. Am. J. Surg. Pathol. 2012, 36, 1874–1882.
147. Fonmarty, D.; Cherriere, S.; Fleury, H.; Eimer, S.; Majoufre-Lefebvre, C.; Castetbon, V.; de Mones, E. Study of the concordance between p16 immunohistochemistry and HPV-pcr genotyping for the viral diagnosis of oropharyngeal squamous cell carcinoma. Eur. Ann. Otorhinolaryngol. Head Neck Dis. 2015, 132, 135–139.
148. Shi, W.; Kato, H.; Perez-Ordonez, B.; Pintilie, M.; Huang, S.; Hui, A.; O’Sullivan, B.; Waldron, J.; Cummings, B.; Kim, J.; et al. Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J. Clin. Oncol. 2009, 27, 6213–6221.
149. Mirghani, H.; Amen, F.; Blanchard, P.; Moreau, F.; Guigay, J.; Hartl, D.M.; Lacau St Guily, J. Treatment de-escalation in HPV-positive oropharyngeal carcinoma: Ongoing trials, critical issues and perspectives. Int. J. Cancer. 2015, 136, 1494–1503.
150. Dorsey, K.; Agulnik, M. Promising new molecular targeted therapies in head and neck cancer. Drugs 2013, 73, 315–325.
151. Kumar, B.; Cordell, K.G.; Lee, J.S.; Worden, F.P.; Prince, M.E.; Tran, H.H.; Wolf, G.T.; Urba, S.G.; Chepeha, D.B.; Teknos, T.N.; et al. Egfr, p16, HPV titer, bcl-xl and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J. Clin. Oncol. 2008, 26, 3128–3137.
152. Bonner, J.A.; Harari, P.M.; Giralt, J.; Azarnia, N.; Shin, D.M.; Cohen, R.B.; Jones, C.U.; Sur, R.; Raben, D.; Jassem, J.; et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 2006, 354, 567–578.
153. Lechner, M.; Frampton, G.M.; Fenton, T.; Feber, A.; Palmer, G.; Jay, A.; Pillay, N.; Forster, M.; Cronin, M.T.; Lipson, D.; et al. Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPV- tumors. Genome Med. 2013,5.
154. Aderhold, C.; Faber, A.; Umbreit, C.; Chakraborty, A.; Bockmayer, A.; Birk, R.; Sommer, J.U.; Hormann, K.; Schultz, J.D. Small molecules alter vegfr and pten expression in HPV-positive and -negative scc: New hope for targeted-therapy. Anticancer Res. 2015, 35, 1389–1399.
155. Argiris, A.; Kotsakis, A.P.; Hoang, T.; Worden, F.P.; Savvides, P.; Gibson, M.K.; Gyanchandani, R.; Blumenschein, G.R., Jr.; Chen, H.X.; Grandis, J.R.; et al. Cetuximab and bevacizumab: Preclinical data and phase ii trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann. Oncol. 2013, 24, 220–225.
156. Aderhold, C.; Faber, A.; Grobschmidt, G.M.; Chakraborty, A.; Bockmayer, A.; Umbreit, C.; Birk, R.; Stern-Straeter, J.; Hormann, K.; Schultz, J.D. Small molecule-based chemotherapeutic approach in p16-positive and -negative hnscc in vitro. Anticancer Res. 2013, 33, 5385–5393.
157. Griffin, H.; Elston, R.; Jackson, D.; Ansell, K.; Coleman, M.; Winter, G.; Doorbar, J. Inhibition of papillomavirus protein function in cervical cancer cells by intrabody targeting. J. Mol. Biol. 2006,355, 360–378.
158. Duenas-Gonzalez, A.; Cetina, L.; Coronel, J.; Cervantes-Madrid, D. Emerging drugs for cervical cancer. Expert Opin. Emerg. Drugs 2012, 17, 203–218.
159. Zhao, C.Y.; Szekely, L.; Bao, W.; Selivanova, G. Rescue of p53 function by small-molecule rita in cervical carcinoma by blocking E6-mediated degradation. Cancer Res. 2010, 70, 3372–3381.
160. Malecka, K.A.; Fera, D.; Schultz, D.C.; Hodawadekar, S.; Reichman, M.; Donover, P.S.; Murphy, M.E.; Marmorstein, R. Identification and characterization of small molecule human papillomavirus E6 inhibitors. ACS Chem. Biol. 2014, 9, 1603–1612.
161. Smukste, I.; Bhalala, O.; Persico, M.; Stockwell, B.R. Using small molecules to overcome drug resistance induced by a viral oncogene. Cancer Cell 2006, 9, 133–146.
162. Cho, Y.; Cho, C.; Joung, O.; Lee, K.; Park, S.; Yoon, D. Development of screening systems for drugs against human papillomavirus-associated cervical cancer: Based on E6-E6AP binding.Antivir. Res. 2000, 47, 199–206.
163. Issaeva, N.; Bozko, P.; Enge, M.; Protopopova, M.; Verhoef, L.G.; Masucci, M.; Pramanik, A.; Selivanova, G. Small molecule rita binds to p53, blocks p53-hdm-2 interaction and activates p53 function in tumors. Nat. Med. 2004, 10, 1321–1328.
164. Xie, X.; Piao, L.; Bullock, B.N.; Smith, A.; Su, T.; Zhang, M.; Teknos, T.N.; Arora, P.S.; Pan, Q. Targeting HPV16 E6-p300 interaction reactivates p53 and inhibits the tumorigenicity of HPV-positive head and neck squamous cell carcinoma. Oncogene 2014, 33, 1037–1046.
165. Yazbeck, V.Y.; Li, C.; Grandis, J.R.; Zang, Y.; Johnson, D.E. Single-agent obatoclax (gx15–070) potently induces apoptosis and pro-survival autophagy in head and neck squamous cell carcinoma cells. Oral Oncol. 2014, 50, 120–127.
166. Yuan, C.H.; Filippova, M.; Tungteakkhun, S.S.; Duerksen-Hughes, P.J.; Krstenansky, J.L. Small molecule inhibitors of the HPV16-E6 interaction with caspase 8. Bioorganic Med. Chem. Lett.2012, 22, 2125–2129.
167. Garnett, T.O.; Filippova, M.; Duerksen-Hughes, P.J. Bid is cleaved upstream of caspase-8 activation during trail-mediated apoptosis in human osteosarcoma cells. Apoptosis 2007, 12, 1299–1315.
168. Fera, D.; Schultz, D.C.; Hodawadekar, S.; Reichman, M.; Donover, P.S.; Melvin, J.; Troutman, S.; Kissil, J.L.; Huryn, D.M.; Marmorstein, R. Identification and characterization of small molecule antagonists of prb inactivation by viral oncoproteins. Chem. Biol. 2012, 19, 518–528.
169. Shaikh, F.; Sanehi, P.; Rawal, R. Molecular screening of compounds to the predicted protein-protein interaction site of rb1-E7 with p53- E6 in HPV. Bioinformation 2012, 8, 607–612.